Biotech Values

[DewDiligence]

OSIP – Now that Lucentis has been approved with a broad and clean label, the latest nonsense to appear on the OSIP ymb is that EyeTech must have brought with it some ace in the hole else OSIP would not have done the EyeTech deal.

In case anyone thinks this ace in the hole is a library of aptamers or the IP to enable the development of aptamer drugs, think again. OSIP owns the rights only to Macugen and any other aptamers for ophthalmic applications that EyeTech picked up from Archemix in a 2004 collaboration (#msg-2842395).

Archemix, a private company, owns virtually everything in the aptamer space, except Macugen, by virtue of acquiring GILD’s aptamer library and IP in 2001:

http://www.archemix.com/press/pr_oct01.html

Next case.